CNS drugsHumansAlzheimer DiseaseAtrophyMagnetic Resonance ImagingHippocampus
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional Trials.
Susan Abushakra, P Murali Doraiswamy, John A Hey, Duygu Tosun, Frederik Barkhof, Jerome Barakos, Jeffrey Petrella, J Patrick Kesslak, Aidan Power, Marwan Sabbagh, Anton Porsteinsson, Sharon Cohen, Serge Gauthier, Craig Ritchie, David Watson
Published: 202610.1007/s40263-025-01251-y
Abstract
Amyloid-plaque reduction is currently the only recognized surrogate outcome for Alzheimer's disease (AD) trials, allowing accelerated approval of plaque-clearing amyloid antibodies. However, plaque reduction does not facilitate the development of new…
Preview only. Read the full abstract at the source